--- title: "Connect Biopharma Advances Enrolment In Phase 2 Seabreeze STAT Trial For Asthma Drug Rademikibart" type: "News" locale: "en" url: "https://longbridge.com/en/news/283976564.md" description: "Connect Biopharma Holdings Ltd. (CNTB) has announced the advancement of enrolment in the Phase 2 Seabreeze STAT trial for its asthma drug Rademikibart, following a favorable review by an independent data monitoring committee. Rademikibart, a monoclonal antibody targeting IL-4Ra, aims to treat Th2 inflammatory diseases. The committee's interim analysis showed no safety concerns after treating at least 50 patients. Topline data is expected by mid-2026, and the company will coordinate with the FDA for the Phase 3 trial." datetime: "2026-04-24T10:00:59.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/283976564.md) - [en](https://longbridge.com/en/news/283976564.md) - [zh-HK](https://longbridge.com/zh-HK/news/283976564.md) --- # Connect Biopharma Advances Enrolment In Phase 2 Seabreeze STAT Trial For Asthma Drug Rademikibart (RTTNews) - Connect Biopharma Holdings Ltd. (CNTB), a clinical-stage pharmaceutical company, announced on Thursday that it would be proceeding with enrolment for the Phase 2 Seabreeze STAT trial for Rademikibart in treating asthma and COPD, following a review by the independent data monitoring committee. Rademikibart is a fully human monoclonal antibody targeting interleukin-4 receptor alpha (IL-4Ra). By blocking the T-helper 2 (Th2) inflammatory pathway, it can treat Th2 inflammatory diseases like atopic dermatitis, asthma, and chronic obstructive pulmonary disorder (COPD). The independent data monitoring committee reviewed data based on a pre-specified interim analysis of efficacy and reported no safety concerns. The interim review came after treatment of a minimum of 50 patients, and at least 28 days of follow-up. The company plans to release topline data by mid-2026 and will align with the U.S. Food and Drug Administration (FDA) on the Phase 3 clinical trial. CNTB closed Thursday's trading at The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. ### Related Stocks - [CNTB.US](https://longbridge.com/en/quote/CNTB.US.md) - [LABU.US](https://longbridge.com/en/quote/LABU.US.md) - [LABD.US](https://longbridge.com/en/quote/LABD.US.md) - [BIB.US](https://longbridge.com/en/quote/BIB.US.md) - [IBB.US](https://longbridge.com/en/quote/IBB.US.md) - [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md) - [PBE.US](https://longbridge.com/en/quote/PBE.US.md) - [FBT.US](https://longbridge.com/en/quote/FBT.US.md) - [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md) - [XBI.US](https://longbridge.com/en/quote/XBI.US.md) - [BBH.US](https://longbridge.com/en/quote/BBH.US.md) - [NDAQ.US](https://longbridge.com/en/quote/NDAQ.US.md) ## Related News & Research - [GRI Bio Highlights Promising Phase 2a IPF Data, Outlook](https://longbridge.com/en/news/286422240.md) - [Candel Therapeutics Reports Positive Phase 3 Prostate Cancer Trial Data](https://longbridge.com/en/news/286652611.md) - [Eton Pharmaceuticals Adds Another 2026 Launch As It Secures U.S. Rights To IMPAVIDO](https://longbridge.com/en/news/287025596.md) - [Korro Bio To Advance KRRO-111 As Potential Treatment For AATD](https://longbridge.com/en/news/287089978.md) - [](https://longbridge.com/en/news/286807703.md)